PMGC Holdings Inc. ELAB

PMGC's first sponsored SPAC adds a public-market acquisition vehicle to the holding company, targeting aerospace and defense, industrial technology, and critical supply chain manufacturersSponsor position of approximately 2.7 million shares, or roughly 21.4% of NorthStrive Acquisition Corp I.'s Class A shares on an as-converted basis, aligns PMGC with value created through a future business combination NEWPORT BEACH, Calif., Oct. 01, 2026 (GLOBE NEWSWIRE) -- PMGC Holdings Inc. (Nasdaq: ELAB) (“P

Engagement of a leading global contract research organization strengthens the analytical foundation supporting EL-22 and EL-32 as the programs advance toward an IND-enabling development frameworkBuilds on NorthStrive Biosciences’ expanding manufacturing and characterization capabilities behind its engineered probiotic platform targeting muscle preservation, including for patients on GLP-1 weight loss treatments NEWPORT BEACH, Calif., Sept. 29, 2026 (GLOBE NEWSWIRE) -- PMGC Holdings Inc. (Nasdaq:

Binding, interest-bearing payment plan converts PMGC’s 5% net sales royalty into scheduled monthly cash payments to NorthStrive Biosciences through August 2031, creating recurring, non-dilutive cash flowAgreement covers the 2025 royalty and all future royalty and earnout payments, backed by joint and several obligors, mandatory prepayments tied to Longevity capital events, and annual audit rights NEWPORT BEACH, Calif., Sept. 18, 2026 (GLOBE NEWSWIRE) -- PMGC Holdings Inc. (“PMGC” or the “Company

Building on positive Phase III results from the parties' AI-driven drug discovery program, the six-month Expansion Program will narrow the four validated compounds toward a nominated lead and designated backup. The Amendment also strengthens the exclusive Cardiac Disease and Obesity field of use and adds a right of first refusal across the broader cardiometabolic field. NEWPORT BEACH, Calif., Sept. 01, 2026 (GLOBE NEWSWIRE) -- NorthStrive Biosciences Inc. ("NorthStrive Biosciences"), a subsidiar

Company prioritizes disciplined capital allocation while expanding machining capacity, integrating portfolio operations and evaluating robotics and automation to support organic growthNEWPORT BEACH, Calif., Aug. 26, 2026 (GLOBE NEWSWIRE) -- PMGC Holdings Inc. (Nasdaq: ELAB) ("PMGC" or the "Company"), a diversified public holding company executing a targeted growth strategy across U.S.-based precision manufacturing, today announced that, following completion of audit-stage financial due diligence

PMGC Holdings Inc. (NASDAQ:ELAB) has entered into a non-binding term sheet with Australian space technology company Orbit2Orbit Pty Ltd, setting out a potential collaboration spanning space-based biomedical research, aerospace manufacturing and a strategic equity investment.

Proposed Mice2Space spaceflight study would evaluate EL-22 and EL-32 in mice in a real-world microgravity environment, targeting one of the most significant physiological challenges of spaceflight Three-part relationship would expand PMGC’s footprint in the growing commercial space economy through a preferred U.S. manufacturing role for A&B Aerospace and a planned strategic investment in Orbit2Orbit NEWPORT BEACH, Calif., Aug. 25, 2026 (GLOBE NEWSWIRE) -- PMGC Holdings Inc. (Nasdaq: ELAB) (“PMGC

New Filings Extend EL-22 and EL-32 into Spaceflight-Associated Muscle Atrophy, Broadening NorthStrive’s Myostatin and Activin A Intellectual Property Portfolio Across Human Weight-Loss, Space Health and Animal Health Applications The filings are intended to position EL-22 and EL-32 as potential muscle-preservation platforms not only for large terrestrial markets, but also for the emerging medical requirements associated with sustained human presence in space NEWPORT BEACH, Calif., Aug. 21, 2026

NEWPORT BEACH, Calif., Aug. 19, 2026 (GLOBE NEWSWIRE) -- PMGC Holdings Inc. (NASDAQ: ELAB) (“PMGC” or the “Company”) today announced that it will effect a 1-for-10 reverse stock split (the “Split”) of its issued and outstanding and authorized common stock, par value $0.0001 per share (“Common Stock”), effective at 12:00 am, Eastern time, on August 21, 2026. Key Details of the Reverse Stock Split: Conversion Ratio: Every 10 shares of issued and outstanding Common Stock will be consolidated into o

NEWPORT BEACH, Calif., Aug. 14, 2026 (GLOBE NEWSWIRE) -- PMGC Holdings Inc. (Nasdaq: ELAB) ("PMGC" or the "Company"), a diversified holding company, has filed its Quarterly Report on Form 10-Q (the "Quarterly Report") for the three and six months ended June 30, 2026, with the U.S. Securities and Exchange Commission ("SEC"). The Quarterly Report is available on the SEC's website at www.sec.gov under the Company's filings. Q2 2026 was a quarter of meaningful revenue and balance sheet growth, drive

Company Reports 8,095,835 Shares of Common Stock Issued and Outstanding as of July 29, 2026, and Moves to Correct Third-Party Market Data That Understates Its Current Share Count and Market CapitalizationNEWPORT BEACH, Calif., July 29, 2026 (GLOBE NEWSWIRE) -- PMGC Holdings Inc. (Nasdaq: ELAB) (“PMGC” or the “Company”), a diversified public holding company, today confirmed that it is in compliance with Nasdaq’s newly approved Market Value of Listed Securities (“MVLS”) continued-listing requireme

Two-year renewable long-term agreement establishes A&B Aerospace as a precision manufacturing supplier to PAD Group and its subsidiaries across aerospace and defense programs. Agreement enables A&B Aerospace to support purchase orders connected to U.S. federal government prime contracts, subject to applicable FAR and DFARS requirements.NEWPORT BEACH, Calif., July 28, 2026 (GLOBE NEWSWIRE) -- PMGC Holdings Inc. (NASDAQ: ELAB) (the “Company,” “PMGC,” “we,” or “our”), a diversified holding company

Independent third-party validation will assess the patented technology’s software, architecture, and performance under controlled, simulation-based conditionsNEWPORT BEACH, Calif., July 27, 2026 (GLOBE NEWSWIRE) -- NorthStrive Defense Tech LLC (“NorthStrive Defense Tech”), a wholly owned subsidiary of PMGC Holdings Inc. (the “Company”) (NASDAQ: ELAB), today announced that it has entered into a project services agreement with Deploy360 to conduct independent validation and testing of the patented

Definitive license agreement formalizes exclusive, worldwide, sublicensable rights to patented multi-domain drone payload technology for aerospace and defense applicationsAgreement follows the binding term sheet and sponsored research agreement announced earlier this yearLicense covers U.S. Patent No. 12,291,334 and related know-how, with a multi-year development plan targeting prototype completion, non-dilutive funding applications, and first commercial sale NEWPORT BEACH, Calif., July 13, 2026

The planned analytical study is designed to strengthen manufacturing characterization of EL-22 as development of the company’s engineered probiotic therapy continues. Key Investor TakeawaysPMGC Holdings (NASDAQ:ELAB), through subsidiary NorthStrive Biosciences, plans to begin an independent EL-22 FACS analysis program.

Independent flow cytometry (FACS) study will quantify latent myostatin antigen expression on NorthStrive-manufactured Lactobacillus casei and establish comparability against EL-22 material previously manufactured by MOA Life Plus Co. Ltd. Work is intended to strengthen EL-22 product identity and manufacturing consistency as NorthStrive advances a differentiated engineered probiotic designed to help preserve muscle during weight loss, including with GLP-1 receptor agonists NEWPORT BEACH, Calif.,

Strategic consolidation of two precision manufacturing portfolio companies expected to streamline operations, shared resources, and strengthen the companies’ aerospace manufacturing platform NEWPORT BEACH, Calif., July 06, 2026 (GLOBE NEWSWIRE) -- PMGC Holdings Inc. (Nasdaq: ELAB) (“PMGC” or the “Company”) today announced that it has merged AGA Precision Systems LLC (“AGA”) into A&B Aerospace, Inc. (“A&B Aerospace”), with A&B Aerospace expected to be the surviving operating entity. The merger is

Yuva Biosciences' proprietary MitoNova™ AI platform identified small-molecule candidates that were biologically validated in primary human skeletal muscle cells, with multiple candidates increasing ANT1, a mitochondrial protein central to skeletal muscle energy metabolism.Four AI-selected compounds demonstrated ANT1 induction, supporting their further confirmatory testing and development. NEWPORT BEACH, Calif., July 01, 2026 (GLOBE NEWSWIRE) -- NorthStrive Biosciences Inc. ("NorthStrive Bioscien

Filed applications include claims directed to the use of EL-22 and EL-32 for preserving lean muscle mass during GLP-1 and obesity-related weight lossFiled applications include combination and co-administration approaches, including taking EL-22 or EL-32 together with apelin or ursolic acid, compounds associated with muscle support NEWPORT BEACH, Calif., June 18, 2026 (GLOBE NEWSWIRE) -- PMGC Holdings Inc. (Nasdaq: ELAB) ("PMGC" or the "Company") today announced that its wholly-owned subsidiary,

A&B Aerospace, SVM Machining, and AGA Precision Systems Position PMGC’s Precision Manufacturing Platform to Serve Growing Demand Across Satellites, Launch Systems, and Space Infrastructure, such as Space Data Centers NEWPORT BEACH, Calif., June 10, 2026 (GLOBE NEWSWIRE) -- PMGC Holdings Inc. (NASDAQ: ELAB) (the “Company,” “PMGC,” “we,” or “our”), a diversified holding company, highlights that its current precision manufacturing operating subsidiaries currently serve and have the opportunity to f